- Home
- Your Messages
-
Smartest Doc
Test your clinical knowledge against other physicians in the USA by taking our FREE daily quiz!
We invite you to take the "Renal cell carcinoma Quiz"
>> Live Leaderboard
New! PHYSICIAN REVIEW
Assess your general knowledge at the topic level with your personalized scorecard.
Thousands of multiple-choice questions pinpoint your areas of expertise and prep you for exams.
- Physician Jobs (509)
- More
- Other Specialty
Oncology News & Articles
Looking for the latest in oncology clinical literature? You've found the right page. MDLinx Oncology medical editors comb through the top peer-reviewed clinical journals for the articles they think will make a difference to you and your practice. You'll find them organized here by topic including breast, hematologic, thoracic, gastrointestinal and genitourinary cancers. In a matter of minutes, oncologists, oncology nurses, physician assistants and the whole cancer care team can stay current on the literature as it is published.
On this page, you'll also find MDLinx exclusive content, including monthly highlights from our physician editor, D. Scott Cunningham, MD, PhD. We feature clinical pearls as well, from The Smartest Oncologist to oncology topics in The Smartest Pediatrician daily quiz challenges.
Your Unread Messages in Oncology
See All >> Messages include industry-sponsored communications and special communications from MDLinx-
Smartest Doc Challenge
MDLinx
Today Only! We’re helping you prep for your board exams -
D Scott Cunningham MD, PhD
Site Editor, MDLinx
Markers of obesity and inflammation in postmenopausal breast cancer -
Jill Baker
MDLinx Career Center
NPs and PAs play crucial role amid PCP shortage -
MDLinx Reminder
MDLinx
Conference Center Upgraded with New Tools -
MDLinx Top Read
MDLinx
Running from that pile of unread journals?
Articles
Latest (142) Full Text Articles (6313) Focus on Pancreas161 Prostate-cancer mortality at 11 years of follow-up Full Text New England Journal of Medicine, September 20, 2012 Original Publication Date: March 19, 2012 Clinical Article
162 Population pharmacokinetics of busulfan in children: Increased evidence for body surface area and allometric body weight dosing of busulfan in children Full Text Clinical Cancer Research, September 20, 2012 Original Publication Date: September 19, 2011 Clinical Article
163 Prognostic relevance of integrated genetic profiling in acute myeloid leukemia Full Text New England Journal of Medicine, September 20, 2012 Original Publication Date: March 19, 2012 Clinical Article
164 Multiple HLA class I and II associations in classical Hodgkin lymphoma and EBV status defined subgroups Full Text Blood, September 20, 2012 Original Publication Date: September 19, 2011
165 High XRCC1-protein expression is associated with poorer survival in patients with head and neck squamous cell carcinoma Full Text Clinical Cancer Research, September 20, 2012 Original Publication Date: September 20, 2011
166 Insulin-like growth factor binding protein-7 (IGFBP7) functions as a potential tumor suppressor in hepatocellular carcinoma (HCC) Full Text Clinical Cancer Research, September 20, 2012 Original Publication Date: September 20, 2011
167 Yoga for breast cancer patients and survivors: a systematic review and meta-analysis Full Text BMC Cancer, September 20, 2012 Evidence Based Medicine Clinical Article
168 Improvement of quality of life and survival using self-expandable metal stent placement for severe malignant stenosis of the gastric body: a case report Full Text Journal of Medical Case Reports, September 20, 2012
169 Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer Full Text Molecular Cancer, September 20, 2012
170 Coronin 3 promotes gastric cancer metastasis via the up-regulation of MMP-9 and cathepsin K Full Text Molecular Cancer, September 20, 2012
171 Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: The Mito-2 Randomized Phase III Trial Full Text Journal of Clinical Oncology, September 19, 2012 Original Publication Date: August 18, 2011 Clinical Article
172 Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: A multicenter phase II trial of the german chronic lymphocytic leukemia study group Full Text Journal of Clinical Oncology, September 19, 2012 Original Publication Date: August 18, 2011 Clinical Article
173 Randomized, double-blind, controlled trial of early endoscopic ultrasound-guided celiac plexus neurolysis to prevent pain progression in patients with newly diagnosed, painful, inoperable pancreatic cancer Full Text Journal of Clinical Oncology, September 19, 2012 Original Publication Date: August 18, 2011 Clinical Article
174 Androgen deprivation therapy and cardiovascular risk Full Text Journal of Clinical Oncology, September 19, 2012 Original Publication Date: August 18, 2011 Clinical Article
175 Population-based study of competing mortality in head and neck cancer Full Text Journal of Clinical Oncology, September 19, 2012 Original Publication Date: August 18, 2011
176 Outcome analyses after the first admission to an intensive care unit in patients with advanced cancer referred to a phase I clinical trials program Full Text Journal of Clinical Oncology, September 19, 2012 Original Publication Date: August 18, 2011
177 Collaboration of Kras and Androgen Receptor Signaling Stimulates EZH2 Expression and Tumor-Propagating Cells in Prostate Cancer Full Text Cancer Research, September 19, 2012
178 Management of bone metastases in refractory prostate cancer – role of denosumab Full Text Clinical Interventions in Aging, September 19, 2012
179 Predictors of Attendance for Prostate-Specific Antigen Screening Tests and Prostate Biopsy Full Text European Urology, September 19, 2012
180 Retrospective analysis of KRAS status in metastatic colorectal cancer patients: a single-center feasibility study Full Text Clinical and Experimental Gastroenterology, September 19, 2012
Clinical Pearls in Oncology
- The ZORO study demonstrated that the addition of goserelin to neoadjuvant chemotherapy for early breast cancer in premenopausal women resulted in no change in post-chemotherapy rates of amenorrhea
- A little over 50% of tumors in women with ER-positive, node-negative breast cancers will have a RS <18, and current data suggests that these women are UNLIKELY to receive a benefit from adjuvant chemotherapy
- In patients with completely resected ER-positive DCIS when the surgical specimen also has LCIS, consider breast MRI screening in addition to mammography due to the lower sensitivity of mammograms for lobular disease
Highlights in Oncology
VEGFR-1 is a prognostic marker for HCC
As reported in the Journal of Pathology, the expression of vascular endothelial growth factor receptor (VEGFR)-1 is elevated in invasive hepatocellular cancer (HCC) specimens. In a study based on 135 HCC specimens, elevated VEGFR-1 was also associated with worse recurrence-free and overall survival.
Read the article summaryHCC risk increased in patients with AIDS
As reported in Cancer, researchers from the NCI have reported that patients with AIDS have a 4-fold increased risk of HCC compared to the general population. The study findings were based on 615,150 patients with AIDS between 1980 and 2009. The risk for HCC in patients with AIDS was essentially the same during the monotherapy/dual therapy and highly active anti-retroviral therapy eras.
Read the article summaryRAB25 is a prognostic marker for ovarian cancer
As reported in the International Journal of Cancer Research and Treatment, the pre-operative level of RAB25 is a predictor of disease-free survival (HR=18.2) and overall survival (HR=33.6) in patients with ovarian cancer. The study involved 36 and 16 women with ovarian cancer and benign tumors, respectively. The pre-operative cell-free DNA of genes (B2M, RAB25, CLDN4, and ABCF2) were measured and RAB25 was shown to be an independent prognostic factor.
Read the article summaryMost Popular Oncology Articles
Last month's top read Top Articles of 20121 Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial European Journal of Cancer, April 2, 2013
2 R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: Results of the FOLL05 Trial conducted by the Fondazione Italiana Linfomi Journal of Clinical Oncology, April 1, 2013
3 Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013 Mayo Clinic Proceedings, April 2, 2013 Clinical Guideline
4 Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study Annals of Oncology, April 3, 2013
5 Phase 2 study of dose-intense temozolomide in recurrent glioblastoma Neuro-Oncology, April 9, 2013
6 Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study Journal of the National Cancer Institute, April 4, 2013
7 Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments BMC Cancer, April 3, 2013 Free full text
8 Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27--A Randomized Controlled Phase III Trial Journal of Clinical Oncology, February 11, 2013
9 Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial The Lancet Oncology, March 12, 2013
10 Effect of low-dose tamoxifen after surgical excision of ductal intraepithelial neoplasia: results of a large retrospective monoinstitutional cohort study Annals of Oncology, April 1, 2013
11 High pretreatment serum lactate dehydrogenase level correlates with disease relapse and predicts an inferior outcome in locally advanced nasopharyngeal carcinoma European Journal of Cancer, April 5, 2013
12 Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial The Lancet Oncology, April 12, 2013
13 Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202) Journal of Clinical Oncology, April 15, 2013
14 Analysis in early stage triple-negative breast cancer treated with mastectomy without adjuvant radiotherapy: Patterns of failure and prognostic factors Cancer, April 11, 2013
15 Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer Cancer, April 10, 2013
16 Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial The Lancet Oncology, February 15, 2013
17 Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC)±bevacizumab: Results of the randomised GeparQuinto study (GBG 44) European Journal of Cancer, April 5, 2013
18 Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial Annals of Oncology, April 4, 2013
19 Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100) Annals of Oncology, April 16, 2013
20 R-CHOP therapy alone in limited stage diffuse large B-cell lymphoma British Journal of Haematology, March 1, 2013
Indexed Journals in Oncology: Journal of Clinical Oncology, Cancer Research, Annals Oncology more
Other Topics in Oncology
Register now to view all the MDLinx contents (FREE)!
- Stay current on the latest literature, research and clinical news
- Get special communications and offers from MDLinx and our sponsors
- Receive invitations to paid market research
Login
Stay current - Media Tool
♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦
♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦
Close